In conclusion, our real-world data suggest a short rwPFS (less than 5 months) among patients with KRAS G12C mutant NSCLC treated with docetaxel containing regimens in the second line, which is congruent with recently reported results from CodeBreak 200 (a randomized trial comparing sotorasib vs. docetaxel in this patient population).16 The gene discussed is KRAS; the disease is non-small cell lung carcinoma.